(TheNewswire)
LONDON, ONTARIO - TheNewswire - July 5, 2021 - Sernova Corp. (TSXV:SVA)(OTC:SEOVF) (FSE/XETRA:PSH) , a leadingclinical-stage regenerative medicine therapeutics company, held itsannual shareholder meeting (the “Meeting”) via the virtual meetingplatform of TSX Trust Company for the following purposes:
-
1. to elect the Corporation’sboard of directors (the “Board”);
-
2. to appoint theCorporation’s auditor; and
-
3. to pass ordinary resolutionsto amend and restate the Corporation’s Option Plan & DeferredShare Unit Plan (the “Incentive Plan”) for the following purposes:(a) to increase the fixed number maximum of shares reserved for grantof options and (b) to increase the fixed number maximum of DeferredShare Units available for award pursuant to the Deferred Share UnitPlan component of the Incentive Plan.
Results of the Meeting:
-
- Frank A. Holler, Dr. Mohammad Azab, Jeffrey A. Bacha,Deborah M. Brown, James T. Parsons and Dr. Philip M. Toleikis wereelected as members of the Board for the following year;
- Davidson & Company, Chartered ProfessionalAccountants, was appointed auditor of the Corporation for anotheryear; and
- disinterested shareholders approved the increase inthe fixed number maximum of common shares reserved for the grant ofoptions and the increase of the fixed number maximum of deferred shareunits available for award pursuant to the Incentive Plan.
“I would like to thank our shareholders for theirMeeting participation and continuing support. From a financial pointof view combined with our latest encouraging interim diabetes clinicalresults (having established insulin independence in our most advancedstudy patient for over 14 months) and the stage of our advancingpharmaceutical collaborations, Sernova is in the strongest position inits history,” said Dr. Philip Toleikis, President & CEO ofSernova Corp.
Toleikis continued, “Improving the quality of lifefor our patients through expansion of our clinical programs andfurther increasing shareholder value are top priorities as we work toachieve important milestones over the next 6-12 months.”
ABOUT SERNOVA
Sernova is developing regenerative medicine therapeutictechnologies using its Cell Pouch medical device, therapeutic cells(i.e., human donor cells, corrected human cells, stem cell-derivedcells and tissues) and immune protection technologies to improve thetreatment and quality of life of people living with chronic metabolicdiseases such as insulin-dependent diabetes, blood disorders includinghemophilia, and other diseases treated through replacement of proteinsor hormones missing or in short supply within the body. For moreinformation, please visit www.sernova.com .
FOR FURTHER INFORMATION, PLEASECONTACT:
Investor Relations
Sernova Corp.
Tel: (519) 858-5126
investorrelations@sernova.com
www.sernova.com
FORWARD-LOOKING INFORMATION
This release contains statements that, to the extentthey are not recitations of historical facts, may constitute“forward-looking statements” that involve various risks,uncertainties, and assumptions, including, without limitation,statements regarding the prospects, plans, and objectives of thecompany. Wherever possible, but not always, words such as"expects", "plans", "anticipates","believes", "intends", "estimates","projects", "potential for" and similarexpressions, or that events or conditions "will","would", "may", "could" or"should" occur are used to identify forward-lookingstatements. These statements reflect management’s beliefs withrespect to future events, including results of clinical trials, andare based on information currently available to management on the datesuch statements were made. Many factors could cause Sernova’s actualresults, performances or achievements to not be as anticipated,estimated or intended or to differ materially from those expressed orimplied by the forward-looking statements contained in this newsrelease. Many of the factors are beyond our control, including thosecaused by, related to, or impacted by the novel coronavirus pandemic.Investors should consult the company’s quarterly and annual filingsavailable on www.sedar.com for additional information on risks anduncertainties relating to the forward-looking statements. Sernovaexpressly disclaims any intention or obligation to update or reviseany forward-looking statements, whether as a result of newinformation, future events or otherwise.
Neither the TSX Venture Exchange norits Regulation Services Provider (as that term is defined in thepolicies of the TSX Venture Exchange) accepts responsibility for theadequacy or accuracy of this release.
Copyright (c) 2021 TheNewswire - All rights reserved.